MolPharm xPharm- The Comprehensive Pharmacology Reference

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Conley, N. S.
Right arrow Articles by Zeidler, R. B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Conley, N. S.
Right arrow Articles by Zeidler, R. B.

Bleomycin increases superoxide anion generation by pig peripheral alveolar macrophages

NS Conley, JW Yarbro, HA Ferrari and RB Zeidler

Pulmonary fibrosis is the major toxic effect of bleomycin chemotherapy; however, the molecular mechanisms of the pathological process are unknown. Since alveolar macrophages produce toxic oxygen metabolites and these can damage lung cells, the effect of bleomycin on superoxide anion production was investigated in subpopulations of pig alveolar macrophages. Cells were lavaged from the lung and separated into three subpopulations according to their density. Their capacity to generate superoxide anions increased the more distally they were located. Bleomycin (5.0 milliunits/ml) increased the rate of superoxide production by 75 +/- 24% in dense alveolar macrophages located in the lung periphery. Hydrocortisone (10.0 micrograms/ml) inhibited this superoxide production by 33 +/- 10%. Results from this study suggest that an excess production of superoxide anions by alveolar macrophages may be the underlying cause of bleomycin pulmonary toxicity.

Volume 30, Issue 1, pp. 48-52, 07/01/1986
Copyright © 1986 by American Society for Pharmacology and Experimental Therapeutics




This article has been cited by other articles:


Home page
Journal of Pharmacy PracticeHome page
L. E. Davis
Long-Term Complications of Antineoplastic Agents
Journal of Pharmacy Practice, January 1, 1991; 4(2): 131 - 150.
[PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 1986 by the American Society for Pharmacology and Experimental Therapeutics